Active Surveillance
7
3
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (7)
Patients With a Single, Small (2 cm or Less) Cancer Nodule in the Thyroid Gland Will be Offered Active Surveillance Initially for 5 Years. In Case of Cancer Growth or Changes in Ultrasonographic Appearance, Further Treatment Will be Offered.
Dietary Fibre Supplementation to Delay Disease Progression in Early Prostate Cancer
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
Personalized Care Pathways for Bowel Symptoms in Rectal Cancer Patients_contributing Factors (Treatable)
Active Surveillance for Limited GGNs
Surveillance for Multifocal GGNs
Statistical Analysis Plan for the SANO-trial: Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Active Surveillance for Oesophageal Cancer